Eiger BioPharmaceuticals, Inc. announced that it has appointed David Apelian, MD, PhD, MBA, who has served as interim Chief Executive Officer since December 2022, as the Company's next CEO.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.272 USD | +1.00% | -15.52% | -66.26% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-66.26% | 3.37M | |
+17.96% | 44.96B | |
+48.77% | 41.85B | |
+1.17% | 42.65B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- EIGR Stock
- News Eiger BioPharmaceuticals, Inc.
- Eiger Biopharmaceuticals, Inc. Appoints David Apelian, as CEO